Literature DB >> 19820207

A single amino acid controls the functional switch of human constitutive androstane receptor (CAR) 1 to the xenobiotic-sensitive splicing variant CAR3.

Tao Chen1, Leslie M Tompkins, Linhao Li, Haishan Li, Gregory Kim, Yuxin Zheng, Hongbing Wang.   

Abstract

The constitutive androstane receptor (CAR) is constitutively activated in immortalized cell lines independent of xenobiotic stimuli. This feature of CAR has limited its use as a sensor for xenobiotic-induced expression of drug-metabolizing enzymes. Recent reports, however, reveal that a splicing variant of human CAR (hCAR3), which contains an insertion of five amino acids (APYLT), exhibits low basal but xenobiotic-inducible activities in cell-based reporter assays. Nonetheless, the underlying mechanisms of this functional shift are not well understood. We have now generated chimeric constructs containing various residues of the five amino acids of hCAR3 and examined their response to typical hCAR activators. Our results showed that the retention of alanine (hCAR1+A) alone is sufficient to confer the constitutively activated hCAR1 to the xenobiotic-sensitive hCAR3. It is noteworthy that hCAR1+A was significantly activated by a series of known hCAR activators, and displayed activation superior to that of hCAR3. Moreover, intracellular localization assays revealed that hCAR1+A exhibits nuclear accumulation upon 6-(4-chlorophenyl) imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl) oxime (CITCO) treatment in COS1 cells, which differs from the spontaneous nuclear distribution of hCAR1 and the nontranslocatable hCAR3. Mammalian two-hybrid and glutathione S-transferase pull-down assays further demonstrated that hCAR1+A interacts with the coactivator SRC-1 and GRIP-1 at low level before activation, while at significantly enhanced level in the presence of CITCO. Thus, the alanine residue in the insertion of hCAR3 seems in charge of the xenobiotic response of hCAR3 through direct and indirect mechanisms. Activation of hCAR1+A may represent a sensitive avenue for the identification of hCAR activators.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19820207      PMCID: PMC2802468          DOI: 10.1124/jpet.109.159210

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene.

Authors:  T Kawamoto; T Sueyoshi; I Zelko; R Moore; K Washburn; M Negishi
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands.

Authors:  L B Moore; D J Parks; S A Jones; R K Bledsoe; T G Consler; J B Stimmel; B Goodwin; C Liddle; S G Blanchard; T M Willson; J L Collins; S A Kliewer
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

3.  Retinoid X receptor-alpha-dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3).

Authors:  Scott S Auerbach; Matthew A Stoner; Shengzhong Su; Curtis J Omiecinski
Journal:  Mol Pharmacol       Date:  2005-08-11       Impact factor: 4.436

4.  Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor.

Authors:  Wendong Huang; Jun Zhang; Michele Washington; Jun Liu; John M Parant; Guillermina Lozano; David D Moore
Journal:  Mol Endocrinol       Date:  2005-04-14

5.  Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.

Authors:  Oliver Burk; Katja A Arnold; Andreas K Nussler; Elke Schaeffeler; Ekaterina Efimova; Bonnie A Avery; Mitchell A Avery; Martin F Fromm; Michel Eichelbaum
Journal:  Mol Pharmacol       Date:  2005-03-10       Impact factor: 4.436

6.  The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice.

Authors:  Yukio Yamamoto; Rick Moore; Thomas L Goldsworthy; Masahiko Negishi; Robert R Maronpot
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

Review 7.  CAR, the continuously advancing receptor, in drug metabolism and disease.

Authors:  M Qatanani; D D Moore
Journal:  Curr Drug Metab       Date:  2005-08       Impact factor: 3.731

8.  Alternative splicing within the ligand binding domain of the human constitutive androstane receptor.

Authors:  Rajesh S Savkur; Yifei Wu; Kelli S Bramlett; Minmin Wang; Sufang Yao; Douglas Perkins; Michelle Totten; George Searfoss; Timothy P Ryan; Eric W Su; Thomas P Burris
Journal:  Mol Genet Metab       Date:  2003 Sep-Oct       Impact factor: 4.797

9.  Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin.

Authors:  Hongbing Wang; Stephanie Faucette; Rick Moore; Tatsuya Sueyoshi; Masahiko Negishi; Edward LeCluyse
Journal:  J Biol Chem       Date:  2004-04-28       Impact factor: 5.157

10.  Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor.

Authors:  Antonia H Tolson; Haishan Li; Natalie D Eddington; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2009-06-11       Impact factor: 3.922

View more
  25 in total

1.  Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine.

Authors:  Devinder Sharma; Aik Jiang Lau; Matthew A Sherman; Thomas K H Chang
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

2.  Evolutionary history and functional characterization of the amphibian xenosensor CAR.

Authors:  Marianne Mathäs; Oliver Burk; Huan Qiu; Christian Nusshag; Ute Gödtel-Armbrust; Dorothea Baranyai; Shiwei Deng; Kristin Römer; Dieudonné Nem; Björn Windshügel; Leszek Wojnowski
Journal:  Mol Endocrinol       Date:  2011-11-10

3.  Identification of novel activators of constitutive androstane receptor from FDA-approved drugs by integrated computational and biological approaches.

Authors:  Caitlin Lynch; Yongmei Pan; Linhao Li; Stephen S Ferguson; Menghang Xia; Peter W Swaan; Hongbing Wang
Journal:  Pharm Res       Date:  2012-10-23       Impact factor: 4.200

4.  The role of constitutive androstane receptor in oxazaphosphorine-mediated induction of drug-metabolizing enzymes in human hepatocytes.

Authors:  Duan Wang; Linhao Li; Jennifer Fuhrman; Stephen Ferguson; Hongbing Wang
Journal:  Pharm Res       Date:  2011-04-13       Impact factor: 4.200

Review 5.  Mechanisms of xenobiotic receptor activation: Direct vs. indirect.

Authors:  Bryan Mackowiak; Hongbing Wang
Journal:  Biochim Biophys Acta       Date:  2016-02-10

Review 6.  Activation of xenobiotic receptors: driving into the nucleus.

Authors:  Haishan Li; Hongbing Wang
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-04       Impact factor: 4.481

7.  Selective phthalate activation of naturally occurring human constitutive androstane receptor splice variants and the pregnane X receptor.

Authors:  Joshua G DeKeyser; Elizabeth M Laurenzana; Eric C Peterson; Tao Chen; Curtis J Omiecinski
Journal:  Toxicol Sci       Date:  2011-01-12       Impact factor: 4.849

8.  Metformin represses drug-induced expression of CYP2B6 by modulating the constitutive androstane receptor signaling.

Authors:  Hui Yang; Brandy Garzel; Scott Heyward; Timothy Moeller; Paul Shapiro; Hongbing Wang
Journal:  Mol Pharmacol       Date:  2013-11-19       Impact factor: 4.436

9.  Activation of the constitutive androstane receptor inhibits gluconeogenesis without affecting lipogenesis or fatty acid synthesis in human hepatocytes.

Authors:  Caitlin Lynch; Yongmei Pan; Linhao Li; Scott Heyward; Timothy Moeller; Peter W Swaan; Hongbing Wang
Journal:  Toxicol Appl Pharmacol       Date:  2014-05-27       Impact factor: 4.219

10.  Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.

Authors:  Duan Wang; Hongbing Wang
Journal:  Acta Pharm Sin B       Date:  2012-04-01       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.